Satisfaction, Safety and Cost of the Treatment for Multiple Sclerosis Relapse with Intravenous versus Oral Methylprednisolone
Introduction: Relapse is a clinical indication of MS activity. Treatment with corticosteroids is recommended for anti-inflammatory, immunosuppressive effects and reduction in the duration and intensity of symptoms. The dosage of intravenous methylprednisolone (ivMP) is 500-1000 mg daily and that of...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Montserrat Gonzalez-Platas [verfasserIn] Pérez Martín Maria Yaiza [verfasserIn] Espinosa Bueno Inmaculada [verfasserIn] González Perera Itamar [verfasserIn] Díaz Stier Noemi [verfasserIn] Eguía del Río Pablo [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Patient Safety and Quality Improvement Journal - Mashhad University of Medical Sciences, 2014, 6(2018), 4, Seite 0-0 |
|---|---|
| Übergeordnetes Werk: |
volume:6 ; year:2018 ; number:4 ; pages:0-0 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.22038/psj.2018.11702 |
|---|
| Katalog-ID: |
DOAJ052007685 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ052007685 | ||
| 003 | DE-627 | ||
| 005 | 20230501173840.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.22038/psj.2018.11702 |2 doi | |
| 035 | |a (DE-627)DOAJ052007685 | ||
| 035 | |a (DE-599)DOAJcc1046af73fc4c8f8a34f68e8f947fd6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a Montserrat Gonzalez-Platas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Satisfaction, Safety and Cost of the Treatment for Multiple Sclerosis Relapse with Intravenous versus Oral Methylprednisolone |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction: Relapse is a clinical indication of MS activity. Treatment with corticosteroids is recommended for anti-inflammatory, immunosuppressive effects and reduction in the duration and intensity of symptoms. The dosage of intravenous methylprednisolone (ivMP) is 500-1000 mg daily and that of oral methylprednisolone (oMP) is 500-1250 mg daily for 3-5 days. There are no differences in the immune, clinical and radiological response between the two administration routes. Tolerance is good. The main objective of this study is to determine the degree of satisfaction of treatment with oMP versus ivMP. The secondary objectives are: to evaluate clinical recovery, side effects and costs. Materials and Methods: 52 Patients received both oMP and ivMP as treatment for MS relapse in the period 2010-2014. All the patients answered a questionnaire. The cost analysis was performed with the HUC costing schedule. Results: 58% of the MS patients said that oral administration was the most comfortable way to treat a relapse. The side effects were similar. Patients positively valued not having to go to hospital (92%), or going to the hospital day-case unit (86%). The overall satisfaction score was 6.7 (max 10) for oMP and 6.5 for ivMP The severity and recovery times for the relapse were similar (56%). The cost of a relapse treated with oMP was €166.23, €575.5 for ivMP and the costs of the day-case unit services were €1130. Conclusions: oMP can be considered as a satisfactory, comfortable and safe alternative in the treatment of an MS relapse. There is a notable monetary saving. | ||
| 650 | 4 | |a Intravenous methylprednisolone | |
| 650 | 4 | |a Multiple sclerosis relapse | |
| 650 | 4 | |a Oral methylprednisolone | |
| 650 | 4 | |a Satisfaction | |
| 650 | 4 | |a Treatment Costs | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a Pérez Martín Maria Yaiza |e verfasserin |4 aut | |
| 700 | 0 | |a Espinosa Bueno Inmaculada |e verfasserin |4 aut | |
| 700 | 0 | |a González Perera Itamar |e verfasserin |4 aut | |
| 700 | 0 | |a Díaz Stier Noemi |e verfasserin |4 aut | |
| 700 | 0 | |a Eguía del Río Pablo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Patient Safety and Quality Improvement Journal |d Mashhad University of Medical Sciences, 2014 |g 6(2018), 4, Seite 0-0 |w (DE-627)1760649864 |x 23454490 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2018 |g number:4 |g pages:0-0 |
| 856 | 4 | 0 | |u https://doi.org/10.22038/psj.2018.11702 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/cc1046af73fc4c8f8a34f68e8f947fd6 |z kostenfrei |
| 856 | 4 | 0 | |u http://psj.mums.ac.ir/article_11702_d41d8cd98f00b204e9800998ecf8427e.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2345-4482 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2345-4490 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2018 |e 4 |h 0-0 | ||
| author_variant |
m g p mgp p m m y pmmy e b i ebi g p i gpi d s n dsn e d r p edrp |
|---|---|
| matchkey_str |
article:23454490:2018----::aifcinaeyncsoteramnfrutpeceoirlpeihnrvnu |
| hierarchy_sort_str |
2018 |
| callnumber-subject-code |
R |
| publishDate |
2018 |
| allfields |
10.22038/psj.2018.11702 doi (DE-627)DOAJ052007685 (DE-599)DOAJcc1046af73fc4c8f8a34f68e8f947fd6 DE-627 ger DE-627 rakwb eng R5-920 Montserrat Gonzalez-Platas verfasserin aut Satisfaction, Safety and Cost of the Treatment for Multiple Sclerosis Relapse with Intravenous versus Oral Methylprednisolone 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: Relapse is a clinical indication of MS activity. Treatment with corticosteroids is recommended for anti-inflammatory, immunosuppressive effects and reduction in the duration and intensity of symptoms. The dosage of intravenous methylprednisolone (ivMP) is 500-1000 mg daily and that of oral methylprednisolone (oMP) is 500-1250 mg daily for 3-5 days. There are no differences in the immune, clinical and radiological response between the two administration routes. Tolerance is good. The main objective of this study is to determine the degree of satisfaction of treatment with oMP versus ivMP. The secondary objectives are: to evaluate clinical recovery, side effects and costs. Materials and Methods: 52 Patients received both oMP and ivMP as treatment for MS relapse in the period 2010-2014. All the patients answered a questionnaire. The cost analysis was performed with the HUC costing schedule. Results: 58% of the MS patients said that oral administration was the most comfortable way to treat a relapse. The side effects were similar. Patients positively valued not having to go to hospital (92%), or going to the hospital day-case unit (86%). The overall satisfaction score was 6.7 (max 10) for oMP and 6.5 for ivMP The severity and recovery times for the relapse were similar (56%). The cost of a relapse treated with oMP was €166.23, €575.5 for ivMP and the costs of the day-case unit services were €1130. Conclusions: oMP can be considered as a satisfactory, comfortable and safe alternative in the treatment of an MS relapse. There is a notable monetary saving. Intravenous methylprednisolone Multiple sclerosis relapse Oral methylprednisolone Satisfaction Treatment Costs Medicine (General) Pérez Martín Maria Yaiza verfasserin aut Espinosa Bueno Inmaculada verfasserin aut González Perera Itamar verfasserin aut Díaz Stier Noemi verfasserin aut Eguía del Río Pablo verfasserin aut In Patient Safety and Quality Improvement Journal Mashhad University of Medical Sciences, 2014 6(2018), 4, Seite 0-0 (DE-627)1760649864 23454490 nnns volume:6 year:2018 number:4 pages:0-0 https://doi.org/10.22038/psj.2018.11702 kostenfrei https://doaj.org/article/cc1046af73fc4c8f8a34f68e8f947fd6 kostenfrei http://psj.mums.ac.ir/article_11702_d41d8cd98f00b204e9800998ecf8427e.pdf kostenfrei https://doaj.org/toc/2345-4482 Journal toc kostenfrei https://doaj.org/toc/2345-4490 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 6 2018 4 0-0 |
| spelling |
10.22038/psj.2018.11702 doi (DE-627)DOAJ052007685 (DE-599)DOAJcc1046af73fc4c8f8a34f68e8f947fd6 DE-627 ger DE-627 rakwb eng R5-920 Montserrat Gonzalez-Platas verfasserin aut Satisfaction, Safety and Cost of the Treatment for Multiple Sclerosis Relapse with Intravenous versus Oral Methylprednisolone 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: Relapse is a clinical indication of MS activity. Treatment with corticosteroids is recommended for anti-inflammatory, immunosuppressive effects and reduction in the duration and intensity of symptoms. The dosage of intravenous methylprednisolone (ivMP) is 500-1000 mg daily and that of oral methylprednisolone (oMP) is 500-1250 mg daily for 3-5 days. There are no differences in the immune, clinical and radiological response between the two administration routes. Tolerance is good. The main objective of this study is to determine the degree of satisfaction of treatment with oMP versus ivMP. The secondary objectives are: to evaluate clinical recovery, side effects and costs. Materials and Methods: 52 Patients received both oMP and ivMP as treatment for MS relapse in the period 2010-2014. All the patients answered a questionnaire. The cost analysis was performed with the HUC costing schedule. Results: 58% of the MS patients said that oral administration was the most comfortable way to treat a relapse. The side effects were similar. Patients positively valued not having to go to hospital (92%), or going to the hospital day-case unit (86%). The overall satisfaction score was 6.7 (max 10) for oMP and 6.5 for ivMP The severity and recovery times for the relapse were similar (56%). The cost of a relapse treated with oMP was €166.23, €575.5 for ivMP and the costs of the day-case unit services were €1130. Conclusions: oMP can be considered as a satisfactory, comfortable and safe alternative in the treatment of an MS relapse. There is a notable monetary saving. Intravenous methylprednisolone Multiple sclerosis relapse Oral methylprednisolone Satisfaction Treatment Costs Medicine (General) Pérez Martín Maria Yaiza verfasserin aut Espinosa Bueno Inmaculada verfasserin aut González Perera Itamar verfasserin aut Díaz Stier Noemi verfasserin aut Eguía del Río Pablo verfasserin aut In Patient Safety and Quality Improvement Journal Mashhad University of Medical Sciences, 2014 6(2018), 4, Seite 0-0 (DE-627)1760649864 23454490 nnns volume:6 year:2018 number:4 pages:0-0 https://doi.org/10.22038/psj.2018.11702 kostenfrei https://doaj.org/article/cc1046af73fc4c8f8a34f68e8f947fd6 kostenfrei http://psj.mums.ac.ir/article_11702_d41d8cd98f00b204e9800998ecf8427e.pdf kostenfrei https://doaj.org/toc/2345-4482 Journal toc kostenfrei https://doaj.org/toc/2345-4490 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 6 2018 4 0-0 |
| allfields_unstemmed |
10.22038/psj.2018.11702 doi (DE-627)DOAJ052007685 (DE-599)DOAJcc1046af73fc4c8f8a34f68e8f947fd6 DE-627 ger DE-627 rakwb eng R5-920 Montserrat Gonzalez-Platas verfasserin aut Satisfaction, Safety and Cost of the Treatment for Multiple Sclerosis Relapse with Intravenous versus Oral Methylprednisolone 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: Relapse is a clinical indication of MS activity. Treatment with corticosteroids is recommended for anti-inflammatory, immunosuppressive effects and reduction in the duration and intensity of symptoms. The dosage of intravenous methylprednisolone (ivMP) is 500-1000 mg daily and that of oral methylprednisolone (oMP) is 500-1250 mg daily for 3-5 days. There are no differences in the immune, clinical and radiological response between the two administration routes. Tolerance is good. The main objective of this study is to determine the degree of satisfaction of treatment with oMP versus ivMP. The secondary objectives are: to evaluate clinical recovery, side effects and costs. Materials and Methods: 52 Patients received both oMP and ivMP as treatment for MS relapse in the period 2010-2014. All the patients answered a questionnaire. The cost analysis was performed with the HUC costing schedule. Results: 58% of the MS patients said that oral administration was the most comfortable way to treat a relapse. The side effects were similar. Patients positively valued not having to go to hospital (92%), or going to the hospital day-case unit (86%). The overall satisfaction score was 6.7 (max 10) for oMP and 6.5 for ivMP The severity and recovery times for the relapse were similar (56%). The cost of a relapse treated with oMP was €166.23, €575.5 for ivMP and the costs of the day-case unit services were €1130. Conclusions: oMP can be considered as a satisfactory, comfortable and safe alternative in the treatment of an MS relapse. There is a notable monetary saving. Intravenous methylprednisolone Multiple sclerosis relapse Oral methylprednisolone Satisfaction Treatment Costs Medicine (General) Pérez Martín Maria Yaiza verfasserin aut Espinosa Bueno Inmaculada verfasserin aut González Perera Itamar verfasserin aut Díaz Stier Noemi verfasserin aut Eguía del Río Pablo verfasserin aut In Patient Safety and Quality Improvement Journal Mashhad University of Medical Sciences, 2014 6(2018), 4, Seite 0-0 (DE-627)1760649864 23454490 nnns volume:6 year:2018 number:4 pages:0-0 https://doi.org/10.22038/psj.2018.11702 kostenfrei https://doaj.org/article/cc1046af73fc4c8f8a34f68e8f947fd6 kostenfrei http://psj.mums.ac.ir/article_11702_d41d8cd98f00b204e9800998ecf8427e.pdf kostenfrei https://doaj.org/toc/2345-4482 Journal toc kostenfrei https://doaj.org/toc/2345-4490 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 6 2018 4 0-0 |
| allfieldsGer |
10.22038/psj.2018.11702 doi (DE-627)DOAJ052007685 (DE-599)DOAJcc1046af73fc4c8f8a34f68e8f947fd6 DE-627 ger DE-627 rakwb eng R5-920 Montserrat Gonzalez-Platas verfasserin aut Satisfaction, Safety and Cost of the Treatment for Multiple Sclerosis Relapse with Intravenous versus Oral Methylprednisolone 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: Relapse is a clinical indication of MS activity. Treatment with corticosteroids is recommended for anti-inflammatory, immunosuppressive effects and reduction in the duration and intensity of symptoms. The dosage of intravenous methylprednisolone (ivMP) is 500-1000 mg daily and that of oral methylprednisolone (oMP) is 500-1250 mg daily for 3-5 days. There are no differences in the immune, clinical and radiological response between the two administration routes. Tolerance is good. The main objective of this study is to determine the degree of satisfaction of treatment with oMP versus ivMP. The secondary objectives are: to evaluate clinical recovery, side effects and costs. Materials and Methods: 52 Patients received both oMP and ivMP as treatment for MS relapse in the period 2010-2014. All the patients answered a questionnaire. The cost analysis was performed with the HUC costing schedule. Results: 58% of the MS patients said that oral administration was the most comfortable way to treat a relapse. The side effects were similar. Patients positively valued not having to go to hospital (92%), or going to the hospital day-case unit (86%). The overall satisfaction score was 6.7 (max 10) for oMP and 6.5 for ivMP The severity and recovery times for the relapse were similar (56%). The cost of a relapse treated with oMP was €166.23, €575.5 for ivMP and the costs of the day-case unit services were €1130. Conclusions: oMP can be considered as a satisfactory, comfortable and safe alternative in the treatment of an MS relapse. There is a notable monetary saving. Intravenous methylprednisolone Multiple sclerosis relapse Oral methylprednisolone Satisfaction Treatment Costs Medicine (General) Pérez Martín Maria Yaiza verfasserin aut Espinosa Bueno Inmaculada verfasserin aut González Perera Itamar verfasserin aut Díaz Stier Noemi verfasserin aut Eguía del Río Pablo verfasserin aut In Patient Safety and Quality Improvement Journal Mashhad University of Medical Sciences, 2014 6(2018), 4, Seite 0-0 (DE-627)1760649864 23454490 nnns volume:6 year:2018 number:4 pages:0-0 https://doi.org/10.22038/psj.2018.11702 kostenfrei https://doaj.org/article/cc1046af73fc4c8f8a34f68e8f947fd6 kostenfrei http://psj.mums.ac.ir/article_11702_d41d8cd98f00b204e9800998ecf8427e.pdf kostenfrei https://doaj.org/toc/2345-4482 Journal toc kostenfrei https://doaj.org/toc/2345-4490 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 6 2018 4 0-0 |
| allfieldsSound |
10.22038/psj.2018.11702 doi (DE-627)DOAJ052007685 (DE-599)DOAJcc1046af73fc4c8f8a34f68e8f947fd6 DE-627 ger DE-627 rakwb eng R5-920 Montserrat Gonzalez-Platas verfasserin aut Satisfaction, Safety and Cost of the Treatment for Multiple Sclerosis Relapse with Intravenous versus Oral Methylprednisolone 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: Relapse is a clinical indication of MS activity. Treatment with corticosteroids is recommended for anti-inflammatory, immunosuppressive effects and reduction in the duration and intensity of symptoms. The dosage of intravenous methylprednisolone (ivMP) is 500-1000 mg daily and that of oral methylprednisolone (oMP) is 500-1250 mg daily for 3-5 days. There are no differences in the immune, clinical and radiological response between the two administration routes. Tolerance is good. The main objective of this study is to determine the degree of satisfaction of treatment with oMP versus ivMP. The secondary objectives are: to evaluate clinical recovery, side effects and costs. Materials and Methods: 52 Patients received both oMP and ivMP as treatment for MS relapse in the period 2010-2014. All the patients answered a questionnaire. The cost analysis was performed with the HUC costing schedule. Results: 58% of the MS patients said that oral administration was the most comfortable way to treat a relapse. The side effects were similar. Patients positively valued not having to go to hospital (92%), or going to the hospital day-case unit (86%). The overall satisfaction score was 6.7 (max 10) for oMP and 6.5 for ivMP The severity and recovery times for the relapse were similar (56%). The cost of a relapse treated with oMP was €166.23, €575.5 for ivMP and the costs of the day-case unit services were €1130. Conclusions: oMP can be considered as a satisfactory, comfortable and safe alternative in the treatment of an MS relapse. There is a notable monetary saving. Intravenous methylprednisolone Multiple sclerosis relapse Oral methylprednisolone Satisfaction Treatment Costs Medicine (General) Pérez Martín Maria Yaiza verfasserin aut Espinosa Bueno Inmaculada verfasserin aut González Perera Itamar verfasserin aut Díaz Stier Noemi verfasserin aut Eguía del Río Pablo verfasserin aut In Patient Safety and Quality Improvement Journal Mashhad University of Medical Sciences, 2014 6(2018), 4, Seite 0-0 (DE-627)1760649864 23454490 nnns volume:6 year:2018 number:4 pages:0-0 https://doi.org/10.22038/psj.2018.11702 kostenfrei https://doaj.org/article/cc1046af73fc4c8f8a34f68e8f947fd6 kostenfrei http://psj.mums.ac.ir/article_11702_d41d8cd98f00b204e9800998ecf8427e.pdf kostenfrei https://doaj.org/toc/2345-4482 Journal toc kostenfrei https://doaj.org/toc/2345-4490 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 6 2018 4 0-0 |
| language |
English |
| source |
In Patient Safety and Quality Improvement Journal 6(2018), 4, Seite 0-0 volume:6 year:2018 number:4 pages:0-0 |
| sourceStr |
In Patient Safety and Quality Improvement Journal 6(2018), 4, Seite 0-0 volume:6 year:2018 number:4 pages:0-0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Intravenous methylprednisolone Multiple sclerosis relapse Oral methylprednisolone Satisfaction Treatment Costs Medicine (General) |
| isfreeaccess_bool |
true |
| container_title |
Patient Safety and Quality Improvement Journal |
| authorswithroles_txt_mv |
Montserrat Gonzalez-Platas @@aut@@ Pérez Martín Maria Yaiza @@aut@@ Espinosa Bueno Inmaculada @@aut@@ González Perera Itamar @@aut@@ Díaz Stier Noemi @@aut@@ Eguía del Río Pablo @@aut@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
1760649864 |
| id |
DOAJ052007685 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ052007685</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501173840.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.22038/psj.2018.11702</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ052007685</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcc1046af73fc4c8f8a34f68e8f947fd6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Montserrat Gonzalez-Platas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Satisfaction, Safety and Cost of the Treatment for Multiple Sclerosis Relapse with Intravenous versus Oral Methylprednisolone</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction: Relapse is a clinical indication of MS activity. Treatment with corticosteroids is recommended for anti-inflammatory, immunosuppressive effects and reduction in the duration and intensity of symptoms. The dosage of intravenous methylprednisolone (ivMP) is 500-1000 mg daily and that of oral methylprednisolone (oMP) is 500-1250 mg daily for 3-5 days. There are no differences in the immune, clinical and radiological response between the two administration routes. Tolerance is good. The main objective of this study is to determine the degree of satisfaction of treatment with oMP versus ivMP. The secondary objectives are: to evaluate clinical recovery, side effects and costs. Materials and Methods: 52 Patients received both oMP and ivMP as treatment for MS relapse in the period 2010-2014. All the patients answered a questionnaire. The cost analysis was performed with the HUC costing schedule. Results: 58% of the MS patients said that oral administration was the most comfortable way to treat a relapse. The side effects were similar. Patients positively valued not having to go to hospital (92%), or going to the hospital day-case unit (86%). The overall satisfaction score was 6.7 (max 10) for oMP and 6.5 for ivMP The severity and recovery times for the relapse were similar (56%). The cost of a relapse treated with oMP was €166.23, €575.5 for ivMP and the costs of the day-case unit services were €1130. Conclusions: oMP can be considered as a satisfactory, comfortable and safe alternative in the treatment of an MS relapse. There is a notable monetary saving.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Intravenous methylprednisolone</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple sclerosis relapse</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oral methylprednisolone</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Satisfaction</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment Costs</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pérez Martín Maria Yaiza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Espinosa Bueno Inmaculada</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">González Perera Itamar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Díaz Stier Noemi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eguía del Río Pablo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Patient Safety and Quality Improvement Journal</subfield><subfield code="d">Mashhad University of Medical Sciences, 2014</subfield><subfield code="g">6(2018), 4, Seite 0-0</subfield><subfield code="w">(DE-627)1760649864</subfield><subfield code="x">23454490</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:0-0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.22038/psj.2018.11702</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cc1046af73fc4c8f8a34f68e8f947fd6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://psj.mums.ac.ir/article_11702_d41d8cd98f00b204e9800998ecf8427e.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2345-4482</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2345-4490</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">2018</subfield><subfield code="e">4</subfield><subfield code="h">0-0</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Montserrat Gonzalez-Platas |
| spellingShingle |
Montserrat Gonzalez-Platas misc R5-920 misc Intravenous methylprednisolone misc Multiple sclerosis relapse misc Oral methylprednisolone misc Satisfaction misc Treatment Costs misc Medicine (General) Satisfaction, Safety and Cost of the Treatment for Multiple Sclerosis Relapse with Intravenous versus Oral Methylprednisolone |
| authorStr |
Montserrat Gonzalez-Platas |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760649864 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
R5-920 |
| illustrated |
Not Illustrated |
| issn |
23454490 |
| topic_title |
R5-920 Satisfaction, Safety and Cost of the Treatment for Multiple Sclerosis Relapse with Intravenous versus Oral Methylprednisolone Intravenous methylprednisolone Multiple sclerosis relapse Oral methylprednisolone Satisfaction Treatment Costs |
| topic |
misc R5-920 misc Intravenous methylprednisolone misc Multiple sclerosis relapse misc Oral methylprednisolone misc Satisfaction misc Treatment Costs misc Medicine (General) |
| topic_unstemmed |
misc R5-920 misc Intravenous methylprednisolone misc Multiple sclerosis relapse misc Oral methylprednisolone misc Satisfaction misc Treatment Costs misc Medicine (General) |
| topic_browse |
misc R5-920 misc Intravenous methylprednisolone misc Multiple sclerosis relapse misc Oral methylprednisolone misc Satisfaction misc Treatment Costs misc Medicine (General) |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Patient Safety and Quality Improvement Journal |
| hierarchy_parent_id |
1760649864 |
| hierarchy_top_title |
Patient Safety and Quality Improvement Journal |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760649864 |
| title |
Satisfaction, Safety and Cost of the Treatment for Multiple Sclerosis Relapse with Intravenous versus Oral Methylprednisolone |
| ctrlnum |
(DE-627)DOAJ052007685 (DE-599)DOAJcc1046af73fc4c8f8a34f68e8f947fd6 |
| title_full |
Satisfaction, Safety and Cost of the Treatment for Multiple Sclerosis Relapse with Intravenous versus Oral Methylprednisolone |
| author_sort |
Montserrat Gonzalez-Platas |
| journal |
Patient Safety and Quality Improvement Journal |
| journalStr |
Patient Safety and Quality Improvement Journal |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
txt |
| container_start_page |
0 |
| author_browse |
Montserrat Gonzalez-Platas Pérez Martín Maria Yaiza Espinosa Bueno Inmaculada González Perera Itamar Díaz Stier Noemi Eguía del Río Pablo |
| container_volume |
6 |
| class |
R5-920 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Montserrat Gonzalez-Platas |
| doi_str_mv |
10.22038/psj.2018.11702 |
| author2-role |
verfasserin |
| title_sort |
satisfaction, safety and cost of the treatment for multiple sclerosis relapse with intravenous versus oral methylprednisolone |
| callnumber |
R5-920 |
| title_auth |
Satisfaction, Safety and Cost of the Treatment for Multiple Sclerosis Relapse with Intravenous versus Oral Methylprednisolone |
| abstract |
Introduction: Relapse is a clinical indication of MS activity. Treatment with corticosteroids is recommended for anti-inflammatory, immunosuppressive effects and reduction in the duration and intensity of symptoms. The dosage of intravenous methylprednisolone (ivMP) is 500-1000 mg daily and that of oral methylprednisolone (oMP) is 500-1250 mg daily for 3-5 days. There are no differences in the immune, clinical and radiological response between the two administration routes. Tolerance is good. The main objective of this study is to determine the degree of satisfaction of treatment with oMP versus ivMP. The secondary objectives are: to evaluate clinical recovery, side effects and costs. Materials and Methods: 52 Patients received both oMP and ivMP as treatment for MS relapse in the period 2010-2014. All the patients answered a questionnaire. The cost analysis was performed with the HUC costing schedule. Results: 58% of the MS patients said that oral administration was the most comfortable way to treat a relapse. The side effects were similar. Patients positively valued not having to go to hospital (92%), or going to the hospital day-case unit (86%). The overall satisfaction score was 6.7 (max 10) for oMP and 6.5 for ivMP The severity and recovery times for the relapse were similar (56%). The cost of a relapse treated with oMP was €166.23, €575.5 for ivMP and the costs of the day-case unit services were €1130. Conclusions: oMP can be considered as a satisfactory, comfortable and safe alternative in the treatment of an MS relapse. There is a notable monetary saving. |
| abstractGer |
Introduction: Relapse is a clinical indication of MS activity. Treatment with corticosteroids is recommended for anti-inflammatory, immunosuppressive effects and reduction in the duration and intensity of symptoms. The dosage of intravenous methylprednisolone (ivMP) is 500-1000 mg daily and that of oral methylprednisolone (oMP) is 500-1250 mg daily for 3-5 days. There are no differences in the immune, clinical and radiological response between the two administration routes. Tolerance is good. The main objective of this study is to determine the degree of satisfaction of treatment with oMP versus ivMP. The secondary objectives are: to evaluate clinical recovery, side effects and costs. Materials and Methods: 52 Patients received both oMP and ivMP as treatment for MS relapse in the period 2010-2014. All the patients answered a questionnaire. The cost analysis was performed with the HUC costing schedule. Results: 58% of the MS patients said that oral administration was the most comfortable way to treat a relapse. The side effects were similar. Patients positively valued not having to go to hospital (92%), or going to the hospital day-case unit (86%). The overall satisfaction score was 6.7 (max 10) for oMP and 6.5 for ivMP The severity and recovery times for the relapse were similar (56%). The cost of a relapse treated with oMP was €166.23, €575.5 for ivMP and the costs of the day-case unit services were €1130. Conclusions: oMP can be considered as a satisfactory, comfortable and safe alternative in the treatment of an MS relapse. There is a notable monetary saving. |
| abstract_unstemmed |
Introduction: Relapse is a clinical indication of MS activity. Treatment with corticosteroids is recommended for anti-inflammatory, immunosuppressive effects and reduction in the duration and intensity of symptoms. The dosage of intravenous methylprednisolone (ivMP) is 500-1000 mg daily and that of oral methylprednisolone (oMP) is 500-1250 mg daily for 3-5 days. There are no differences in the immune, clinical and radiological response between the two administration routes. Tolerance is good. The main objective of this study is to determine the degree of satisfaction of treatment with oMP versus ivMP. The secondary objectives are: to evaluate clinical recovery, side effects and costs. Materials and Methods: 52 Patients received both oMP and ivMP as treatment for MS relapse in the period 2010-2014. All the patients answered a questionnaire. The cost analysis was performed with the HUC costing schedule. Results: 58% of the MS patients said that oral administration was the most comfortable way to treat a relapse. The side effects were similar. Patients positively valued not having to go to hospital (92%), or going to the hospital day-case unit (86%). The overall satisfaction score was 6.7 (max 10) for oMP and 6.5 for ivMP The severity and recovery times for the relapse were similar (56%). The cost of a relapse treated with oMP was €166.23, €575.5 for ivMP and the costs of the day-case unit services were €1130. Conclusions: oMP can be considered as a satisfactory, comfortable and safe alternative in the treatment of an MS relapse. There is a notable monetary saving. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA |
| container_issue |
4 |
| title_short |
Satisfaction, Safety and Cost of the Treatment for Multiple Sclerosis Relapse with Intravenous versus Oral Methylprednisolone |
| url |
https://doi.org/10.22038/psj.2018.11702 https://doaj.org/article/cc1046af73fc4c8f8a34f68e8f947fd6 http://psj.mums.ac.ir/article_11702_d41d8cd98f00b204e9800998ecf8427e.pdf https://doaj.org/toc/2345-4482 https://doaj.org/toc/2345-4490 |
| remote_bool |
true |
| author2 |
Pérez Martín Maria Yaiza Espinosa Bueno Inmaculada González Perera Itamar Díaz Stier Noemi Eguía del Río Pablo |
| author2Str |
Pérez Martín Maria Yaiza Espinosa Bueno Inmaculada González Perera Itamar Díaz Stier Noemi Eguía del Río Pablo |
| ppnlink |
1760649864 |
| callnumber-subject |
R - General Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.22038/psj.2018.11702 |
| callnumber-a |
R5-920 |
| up_date |
2024-07-03T23:19:14.398Z |
| _version_ |
1803601842698977280 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ052007685</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501173840.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.22038/psj.2018.11702</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ052007685</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcc1046af73fc4c8f8a34f68e8f947fd6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Montserrat Gonzalez-Platas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Satisfaction, Safety and Cost of the Treatment for Multiple Sclerosis Relapse with Intravenous versus Oral Methylprednisolone</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction: Relapse is a clinical indication of MS activity. Treatment with corticosteroids is recommended for anti-inflammatory, immunosuppressive effects and reduction in the duration and intensity of symptoms. The dosage of intravenous methylprednisolone (ivMP) is 500-1000 mg daily and that of oral methylprednisolone (oMP) is 500-1250 mg daily for 3-5 days. There are no differences in the immune, clinical and radiological response between the two administration routes. Tolerance is good. The main objective of this study is to determine the degree of satisfaction of treatment with oMP versus ivMP. The secondary objectives are: to evaluate clinical recovery, side effects and costs. Materials and Methods: 52 Patients received both oMP and ivMP as treatment for MS relapse in the period 2010-2014. All the patients answered a questionnaire. The cost analysis was performed with the HUC costing schedule. Results: 58% of the MS patients said that oral administration was the most comfortable way to treat a relapse. The side effects were similar. Patients positively valued not having to go to hospital (92%), or going to the hospital day-case unit (86%). The overall satisfaction score was 6.7 (max 10) for oMP and 6.5 for ivMP The severity and recovery times for the relapse were similar (56%). The cost of a relapse treated with oMP was €166.23, €575.5 for ivMP and the costs of the day-case unit services were €1130. Conclusions: oMP can be considered as a satisfactory, comfortable and safe alternative in the treatment of an MS relapse. There is a notable monetary saving.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Intravenous methylprednisolone</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple sclerosis relapse</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oral methylprednisolone</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Satisfaction</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment Costs</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pérez Martín Maria Yaiza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Espinosa Bueno Inmaculada</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">González Perera Itamar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Díaz Stier Noemi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eguía del Río Pablo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Patient Safety and Quality Improvement Journal</subfield><subfield code="d">Mashhad University of Medical Sciences, 2014</subfield><subfield code="g">6(2018), 4, Seite 0-0</subfield><subfield code="w">(DE-627)1760649864</subfield><subfield code="x">23454490</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:0-0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.22038/psj.2018.11702</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cc1046af73fc4c8f8a34f68e8f947fd6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://psj.mums.ac.ir/article_11702_d41d8cd98f00b204e9800998ecf8427e.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2345-4482</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2345-4490</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">2018</subfield><subfield code="e">4</subfield><subfield code="h">0-0</subfield></datafield></record></collection>
|
| score |
7.3998346 |